期刊
ANTIBIOTICS-BASEL
卷 9, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics9080445
关键词
fungal infections; antifungal agents; antifungal drug development
资金
- NIH from the National Institute of Allergy and Infectious Diseases [R21AI140823]
- Margaret Batts Tobin Foundation, San Antonio, TX
- Science, Mathematics, and Research for Transformation (SMART) fellowship by the Department of Defense
Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a limited number of selective targets that can be exploited for antifungal drug development. This has also resulted in a very restricted number of antifungal drugs that are clinically available for the treatment of invasive fungal infections at the present time-polyenes, azoles, echinocandins, and flucytosine. Moreover, the utility of available antifungals is limited by toxicity, drug interactions and the emergence of resistance, which contribute to high morbidity and mortality rates. This review will present a brief summary on the landscape of current antifungals and those at different stages of clinical development. We will also briefly touch upon potential new targets and opportunities for novel antifungal strategies to combat the threat of fungal infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据